The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic syndrome, including antithrombotic effects.
